Compare TOMZ & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | HSCS |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 15.8M |
| IPO Year | 2009 | 2022 |
| Metric | TOMZ | HSCS |
|---|---|---|
| Price | $1.57 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 11.9K | ★ 136.9K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.64 | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | $4,319.00 |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.63 |
| 52 Week High | $2.12 | $4.35 |
| Indicator | TOMZ | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 57.75 |
| Support Level | $0.68 | $1.88 |
| Resistance Level | $1.95 | $3.57 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 10.00 | 39.01 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.